COVID-19 and chronic kidney disease: peculiarities of treatment
Abstract. The present study aimed to characterize the management of patients with chronic kidney disease with concomitant COVID-19. Articles published in 2019-2021 in the PubMed, Scopus, and Google Scholar electronic databases were analyzed. As a result of this review, the following particularities of COVID-19 treatment in chronic kidney disease could be summarized. It is obligatory to continue treatment with renin-angiotensin-aldosterone system inhibitors in patients with chronic kidney disease and COVID-19. Lisinopril is considered used for avoiding the elevated renal expression of angiotensin-converting enzyme 2. Spironolactone can prevent acute lung injuries and is reasonable if the triple combination of drugs for reducing blood pressure is not effective. Low-dose rosuvastatin therapy is recommended for patients with COVID-19 and chronic kidney disease stages 3-5 treated with antiretroviral drugs such as lopinavir and ritonavir, remdesivir. Ezetimibe is reasonable to use in case of ineffective higher doses of statins and to decrease hospitalization risk..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2022 |
|---|---|
| Enthalten in: |
Український Журнал Нефрології та Діалізу - (2022), 2(74) |
| Sprache: |
Englisch ; Russisch ; Ukrainisch |
|---|
| Beteiligte Personen: |
O. Chernatska [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Chronic kidney disease, COVID-19, statins, angiotensin-converting enzyme inhibitors. |
|---|
| doi: |
10.31450/ukrjnd.2(74).2022.11 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ097196908 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ097196908 | ||
| 003 | DE-627 | ||
| 005 | 20240413174651.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240413s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.31450/ukrjnd.2(74).2022.11 |2 doi | |
| 035 | |a (DE-627)DOAJ097196908 | ||
| 035 | |a (DE-599)DOAJedbf0ab95c0343d685cd54e6166f3a27 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng |a rus |a ukr | ||
| 050 | 0 | |a RC870-923 | |
| 100 | 0 | |a O. Chernatska |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 and chronic kidney disease: peculiarities of treatment |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract. The present study aimed to characterize the management of patients with chronic kidney disease with concomitant COVID-19. Articles published in 2019-2021 in the PubMed, Scopus, and Google Scholar electronic databases were analyzed. As a result of this review, the following particularities of COVID-19 treatment in chronic kidney disease could be summarized. It is obligatory to continue treatment with renin-angiotensin-aldosterone system inhibitors in patients with chronic kidney disease and COVID-19. Lisinopril is considered used for avoiding the elevated renal expression of angiotensin-converting enzyme 2. Spironolactone can prevent acute lung injuries and is reasonable if the triple combination of drugs for reducing blood pressure is not effective. Low-dose rosuvastatin therapy is recommended for patients with COVID-19 and chronic kidney disease stages 3-5 treated with antiretroviral drugs such as lopinavir and ritonavir, remdesivir. Ezetimibe is reasonable to use in case of ineffective higher doses of statins and to decrease hospitalization risk. | ||
| 650 | 4 | |a chronic kidney disease, COVID-19, statins, angiotensin-converting enzyme inhibitors. | |
| 653 | 0 | |a Diseases of the genitourinary system. Urology | |
| 700 | 0 | |a A. Grek |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Український Журнал Нефрології та Діалізу |d State Institution «Institute of Nephrology NAMS of Ukraine", 2018 |g (2022), 2(74) |w (DE-627)DOAJ000141488 |x 26167352 |7 nnns |
| 773 | 1 | 8 | |g year:2022 |g number:2(74) |
| 856 | 4 | 0 | |u https://doi.org/10.31450/ukrjnd.2(74).2022.11 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/edbf0ab95c0343d685cd54e6166f3a27 |z kostenfrei |
| 856 | 4 | 0 | |u https://ukrjnd.com.ua/index.php/journal/article/view/620 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2304-0238 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2616-7352 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |j 2022 |e 2(74) | ||